Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · Real-Time Price · USD
13.15
+0.57 (4.53%)
Sep 26, 2025, 4:00 PM EDT - Market closed
Dyne Therapeutics Employees
Dyne Therapeutics had 191 employees as of December 31, 2024. The number of employees increased by 50 or 35.46% compared to the previous year.
Employees
191
Change (1Y)
50
Growth (1Y)
35.46%
Revenue / Employee
n/a
Profits / Employee
-$2,161,707
Market Cap
1.87B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 191 | 50 | 35.46% |
| Dec 31, 2023 | 141 | 22 | 18.49% |
| Dec 31, 2022 | 119 | 26 | 27.96% |
| Dec 31, 2021 | 93 | 46 | 97.87% |
| Dec 31, 2020 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
DYN News
- 18 days ago - Dyne Therapeutics, Inc. (DYN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 4 weeks ago - Dyne Therapeutics to Present at Upcoming Investor Conferences - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) - GlobeNewsWire
- 2 months ago - These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss - Benzinga
- 2 months ago - Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer - Business Wire
- 3 months ago - Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - GlobeNewsWire
- 3 months ago - Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga